Work

Dose-finding combination study of niraparib and pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant epithelial ovarian cancer (OC) (TOPACIO/Keynote-162)

Year: 2017

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx376.009

Authors: P.A. Konstantinopoulos, J.C. Sachdev, L. Schwartzberg, U.A. Matulonis, P. Sun, J.Y. Wang, W. Guo, D. Bobilev, G. Aktan, V. Karantza, B. Dezube, S. Vinayak

Institutions: Dana-Farber Cancer Institute, HonorHealth, Tesaro (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), Case Comprehensive Cancer Center, Case Western Reserve University

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, AstraZeneca, Genentech

OpenAlex ID: W2761728011

FWCI: 0.964

Cites:

Cited by: 12

Related to: 10